FIGHT-MG

"Myasthenias, a group of immune mediated neurological diseases: from etiology to therapy."

 Coordinatore INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) 

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Mrs.
Nome: Isabelle
Cognome: Verdier
Email: send email
Telefono: +33 1 48 07 34 33
Fax: +33 1 48 07 34 32

 Nazionalità Coordinatore France [FR]
 Sito del progetto http://www.fight-mg.eu/
 Totale costo 7˙767˙250 €
 EC contributo 5˙917˙421 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2009-single-stage
 Funding Scheme CP-FP
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-12-01   -   2014-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Mrs.
Nome: Isabelle
Cognome: Verdier
Email: send email
Telefono: +33 1 48 07 34 33
Fax: +33 1 48 07 34 32

FR (PARIS) coordinator 1˙349˙112.88
2    FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA

 Organization address address: VIA CELORIA 11
city: MILANO
postcode: 20133

contact info
Titolo: Dr.
Nome: Francesca
Cognome: Grechi
Email: send email
Telefono: +39 0223942320
Fax: +39 0223942527

IT (MILANO) participant 607˙240.00
3    THE OPEN UNIVERSITY*

 Organization address address: RAVUZKI 108
city: RAANANA
postcode: 43107

contact info
Titolo: Dr.
Nome: Milly
Cognome: Perry
Email: send email
Telefono: +972 9 7781135
Fax: +972 9 7780781

IL (RAANANA) participant 601˙500.00
4    HELLENIC PASTEUR INSTITUTE

 Organization address address: Vassilissis Sofias Avenue 127
city: ATHENS
postcode: 11521

contact info
Titolo: Mr.
Nome: Ioannis
Cognome: Kouskos
Email: send email
Telefono: +30 210 6478849
Fax: +30 210 6440171

EL (ATHENS) participant 600˙300.00
5    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

 Organization address address: TECHNION CITY - SENATE BUILDING
city: HAIFA
postcode: 32000

contact info
Titolo: Mr.
Nome: Jack
Cognome: Lavan
Email: send email
Telefono: +972 4 8293097
Fax: +972 4 8232958

IL (HAIFA) participant 595˙800.00
6    OSLO UNIVERSITETSSYKEHUS HF

 Organization address address: FORSKNINGSVEIEN 2B
city: OSLO
postcode: 373

contact info
Titolo: Ms.
Nome: Kari
Cognome: Kværner
Email: send email
Telefono: +47 22 11 80 80
Fax: +47 22 69 41 73

NO (OSLO) participant 449˙400.00
7    HADASSAH MEDICAL ORGANIZATION

 Organization address address: n/a
city: JERUSALEM
postcode: 91120

contact info
Titolo: Mr.
Nome: Menachem
Cognome: Katz
Email: send email
Telefono: 97226776213
Fax: 97226776200

IL (JERUSALEM) participant 348˙300.00
8    UNIVERSITAET BASEL

 Organization address address: Petersplatz 1
city: BASEL
postcode: 4003

contact info
Titolo: Prof.
Nome: Markus
Cognome: Ruegg
Email: send email
Telefono: +41 61 267 22 23
Fax: +41 61 267 22 08

CH (BASEL) participant 333˙900.00
9    UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

 Organization address address: Place Jussieu 4
city: PARIS
postcode: 75252

contact info
Titolo: Mr.
Nome: Jean-Marc
Cognome: Duclos
Email: send email
Telefono: +33 1 44 27 33 30
Fax: +33 1 44 27 35 31

FR (PARIS) participant 314˙700.00
10    INSERM - TRANSFERT SA

 Organization address address: Rue Watt 7
city: PARIS
postcode: 75013

contact info
Titolo: Mr.
Nome: Louis
Cognome: Jammayrac
Email: send email
Telefono: +33 1 55030101
Fax: +33 1 55030160

FR (PARIS) participant 287˙000.00
11    PROTEOSYS AG

 Organization address address: CARL ZEISSSTRASSE 51
city: MAINZ
postcode: 55129

contact info
Titolo: Dr.
Nome: Markus
Cognome: Bucher
Email: send email
Telefono: +49 6131 5019225
Fax: +49 6131 5019211

DE (MAINZ) participant 270˙268.12
12    GENOPOLIS CONSORZIO DI GENOMICA FUNZIONALE

 Organization address address: PIAZZA DELLA SCIENZA 2 UNIVERSITA DEGLI STUDI MILANO
city: MILAN
postcode: 20126

contact info
Titolo: Ms.
Nome: Erica
Cognome: Lomnes
Email: send email
Telefono: 390264000000
Fax: 390241000000

IT (MILAN) participant 159˙900.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

regulatory    regulators    mouse    mediated    immunological    mesenchymal    mg    gravis    treatment    therapies    assays    aetiology    twins    neurological    stem    mice    autoimmune    associations    disease    therapy    patients    considerable    risk    affecting    fight    pathogenic    affects    cells    muscle    environmental    neuromuscular    molecular    epigenetic    etiology    morphological    immune    subgroups    events    certain    genetic    nerves    patient    biomarkers    course    cell    onset    light    proteomic    myasthenia    quality    rare    models    nmj    molecules    life    microrna   

 Obiettivo del progetto (Objective)

'Myasthenia Gravis (MG) is a heterogeneous rare autoimmune neurological disease affecting the neuromuscular junction (NMJ). The molecular events causing and maintaining MG are still unknown and current treatments do not lead to remission and entail considerable side-effects stressing the need for improved therapies. We will address the: 1. Natural course of disease: determine factors associated with disease onset and/or affecting the course of disease and patients' quality of life in subgroups of MG patients including children, twins, females and elderly patients. 2. Etiology of MG: identify new genetic, epigenetic and environmental risk factors and investigate immunological key molecules associated with MG onset. 3. Pathogenic mechanisms at the NMJ: a) study molecular changes in the NMJ by proteomic, genetic, epigenetic and microRNA analyses in MG patients and experimental models; b) analyze morphological changes at the NMJ in mouse models expressing YFP nerves and mice transgenic for mini-agrin; c) evaluate the capacity of muscle cell satellites from MG patients to regenerate muscle and form new endplates in immunodeficient mice. 4. New diagnostic and monitoring assays: a) identify pathogenic and protective factors in MG sera; b) improve the sensitivity of current assays; c) Identify new biomarkers associated with different MG subgroups by proteomic and microRNA analyses; d) Identify patients' response to treatment and liability to side effects by pharmacogenomic analyses. 5. Novel therapies: a) study new cell-based therapies aimed at regulating the autoimmune response by regulatory T cells or mesenchymal stem cells in humanized mice; b) immunoadsorb pathogenic antibodies; c) test non-cell based immmunomodulatory therapies; d) target epigenetic regulators. This multidisciplinary project linking basic researchers with clinical neurologists, SMEs and several European patient associations should favor a translational approach for improved MG management'

Introduzione (Teaser)

Myasthenia gravis (MG) is a multifactorial disease of genetic and environmental aetiology. Delineating the genetic risk factors and disease triggers is anticipated to aid in the design of novel, targeted therapies.

Descrizione progetto (Article)

MG is a rare autoimmune disorder that affects the neuromuscular junctions, the sites where the nerves attach to the muscle to transmit information. Patients present with abnormal fatigue in various skeletal muscles, which significantly affects their quality of life. Existing therapies are not very effective and often cause uncomfortable side-effects.

Seeking to address this, the EU-funded 'Myasthenias, a group of immune mediated neurological diseases: From etiology to therapy' (http://www.fight-mg.eu/ (FIGHT-MG)) project performed an interdisciplinary investigation into the epidemiology, aetiology and pathological features of MG.

A narrow collaboration between European clinicians, scientists and associations of patients allowed to establish a patient database with information on 4 300 MG patients, the largest collection in Europe, as well as to evaluate the quality of life of the patients.

The main scientific achievements of the project are, first, the identification of several molecules involved in the pathology. To shed light on the genetic and environmental aetiology of the disease, researchers studied monozygotic twins. They found that the epigenetic profile was similar in the twins, even when they were discordant for the disease, but they also detected changes in gene expression that could explain disease onset in the MG versus healthy twin. The work of the consortium focused on molecules implicated in the immune response (IFN type I and TLR), on Th17 cells, on the immune regulator AIRE and on the oncogene VAV1. In a rat model of the disease, they could also detect an immunological imbalance between regulatory T cells and Th17 cells. Secondly, the characterization of the molecular events occurring in the muscle of the MG patients and MG animals. Using mouse models, researchers investigated the molecular pathogenesis of MG by observing morphological alterations in affected muscle. In humans, they identified deregulation in certain miRNA molecules and developed novel assays for the detection of autoantibodies and other serum biomarkers. New biomarkers of therapeutic significance were discovered that could be used to reliably predict the response to certain drugs. Thirdly, the development of innovative therapies. Researchers also developed novel molecular and cell-mediated therapies based on the use of regulatory T cells or mesenchymal stem cells. Treatment with epigenetic regulators or the administration of plasminogen mutant protein showed considerable efficacy in MG animal models.

Taken together, the FIGHT-MG study sheds light on the mechanism of the disease and proposes new promising therapeutics. The more sensitive assays developed during the project should enable prompt diagnosis and help alleviate disease symptoms through early therapy.

Altri progetti dello stesso programma (FP7-HEALTH)

AMPHORA (2009)

Alcohol Measures for Public Health Research Alliance (AMPHORA)

Read More  

PANCARESURFUP (2011)

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies

Read More  

MEMOLOAD (2008)

Neurobiological Mechanisms of Memory Loss in Alzheimer's Disease

Read More